Prexige, Pulled In Australia, Still Viable: Novartis

Law360, New York (August 14, 2007, 12:00 AM EDT) -- Novartis AG has continued to insist that its painkiller Prexige is a viable option for some patients, after the drug was yanked from the Australian market and authorities there urged patients to stop taking it based on reports linking the drug to severe liver damage, allegedly resulting in two deaths and two liver transplants.

Tuesday, Novartis spokesman John Gilardi said that the company still believed that Prexige, which is the brand name for lumiracoxib, should remain an option for doctors and certain patients managing acute pain....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.